CG Oncology targets near $1 bln valuation in US IPO | Reuters

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. ... CG Oncology targets near $1 bln valuation in …

CouponFollow Extension

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

21 hours ago

reuters.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

yahoo.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

21 hours ago

Jan 25 (Reuters) - Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO - Yahoo …

21 hours ago

Jan 18, 2024 · The company is developing a therapy for patients with bladder cancer. Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy for patients...

marketscreener.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO

21 hours ago

Jan 18, 2024 · CG Oncology targets near $1 billion valuation in US IPO. ... January 18, 2024 (Reuters) -Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

westlaw.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Billion …

21 hours ago

Jan 18, 2024 · (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. (Reporting by Niket Nishant in …

kelo.com

$1.75
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

21 hours ago

Jan 25, 2024 · Adds background and context on IPO market in paragraphs 2-3. Jan 25 (Reuters) - Cancer drug developer CG Oncology CGON.O notched up a valuation of $1.75 billion in its …

nasdaq.com

6%
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

21 hours ago

5 days ago · CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. …

stockanalysis.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.The company is developing a therapy for …

tradingview.com

$450
OFF

CG Oncology Inc | Reuters

21 hours ago

Feb 9, 2024 · The latest international CG Oncology Inc news and views from Reuters - one of the world's largest news agencies ... $450 mln in US IPO at over $3 bln valuation. ... CG Oncology …

reuters.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

21 hours ago

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

21 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

21 hours ago

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

0%
OFF

Mohacsy's Safe Portfolio Member Forum : CG Oncology Targets …

21 hours ago

Jan 18, 2024 · dexprs: CG Oncology targets near $1 bln valuation in US IPO REUTERS 6:33 AM ET 1/18/2024 Symbol Last Price Change MRK 118.13down 0 (0%) GILD 86.48down...

advfn.com

FAQs about CG Oncology targets near $1 bln valuation in US IPO | Reuters Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

Will CG oncology raise $100 million in a public offering?

IRVINE, Calif.-- (BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...

Does CG oncology have a bladder cancer trial?

CG Oncology is conducting a late-stage trial of its bladder cancer therapy called cretostimogene grenadenorepvec, an engineered virus that replicates in certain defective cells present in most urothelial carcinomas. Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital are the underwriters to the IPO. ...